Published in ACS Med Chem Lett on October 15, 2013
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (1998) 11.23
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
On the attribution and additivity of binding energies. Proc Natl Acad Sci U S A (1981) 4.44
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 3.60
Mammalian deoxyribonucleoside kinases. Pharmacol Ther (1995) 3.31
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A (2008) 2.82
Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1995) 1.84
Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev (2000) 1.47
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett (2001) 1.44
Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun (1991) 1.44
Discovering high-affinity ligands for proteins. Science (1997) 1.33
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc (2008) 1.29
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem (2004) 1.21
Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther (2003) 1.18
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase. J Med Chem (2000) 1.09
Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity. Biochemistry (2008) 1.03
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry (2006) 0.98
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem (2005) 0.97
Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J Med Chem (1995) 0.91
[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase. Bioorg Med Chem (2010) 0.91
Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities. J Med Chem (2002) 0.88
Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. J Med Chem (1999) 0.87
Current developments in the synthesis and biological activity of HIV-1 double-drug inhibitors. Curr Med Chem (2007) 0.86
Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids (2002) 0.84
Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation. Antivir Chem Chemother (1998) 0.83
Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract. Antiviral Res (2012) 0.83
Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine. Antiviral Res (2004) 0.81
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy. J Med Chem (2013) 0.80
Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[trovirdine analogue] of known HIV-1 reverse transcriptase inhibitors. J Enzyme Inhib Med Chem (2003) 0.80
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond. J Med Chem (2004) 0.80
[Nikavir in chemoprevention regimens for vertical HIV infection transmission]. Vopr Virusol (2010) 0.79
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate. Bioorg Med Chem Lett (2012) 0.78
Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res (1996) 0.78
Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir. Biochem Pharmacol (2004) 0.77
Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorg Med Chem (2001) 0.77